Factors Informing Individualized Treatment Decision-Making for HER2-Positive Metastatic Breast Cancer


Sara M. Tolaney, MD, MPH explains that treatment decisions for metastatic breast cancer are based on the current biopsy showing receptor status, but prior biopsies over the full course of disease are considered as well, particularly for HER2 targeted therapies which may work even if HER2 low expression occurred years earlier.

Related Videos
Sue Friedman in an interview with CURE
Catrina Crutcher in an interview with CURE
Related Content